BRPI0815048A2 - derivado de fenóxi-pirrolidinas e uso e composições do mesmo - Google Patents
derivado de fenóxi-pirrolidinas e uso e composições do mesmoInfo
- Publication number
- BRPI0815048A2 BRPI0815048A2 BRPI0815048A BRPI0815048A BRPI0815048A2 BR PI0815048 A2 BRPI0815048 A2 BR PI0815048A2 BR PI0815048 A BRPI0815048 A BR PI0815048A BR PI0815048 A BRPI0815048 A BR PI0815048A BR PI0815048 A2 BRPI0815048 A2 BR PI0815048A2
- Authority
- BR
- Brazil
- Prior art keywords
- phenoxy
- compositions
- pyrrolidines
- derivative
- pyrrolidines derivative
- Prior art date
Links
- AUSRRRUBMHIEJD-UHFFFAOYSA-N 1-phenoxypyrrolidine Chemical class C1CCCN1OC1=CC=CC=C1 AUSRRRUBMHIEJD-UHFFFAOYSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- MZYNHNDFHWNIIU-UHFFFAOYSA-N 2-[4-(hydroxymethyl)phenoxy]-1-[3-[2-(trifluoromethyl)phenoxy]pyrrolidin-1-yl]ethanone Chemical compound C1=CC(CO)=CC=C1OCC(=O)N1CC(OC=2C(=CC=CC=2)C(F)(F)F)CC1 MZYNHNDFHWNIIU-UHFFFAOYSA-N 0.000 abstract 1
- 108010087894 Fatty acid desaturases Proteins 0.000 abstract 1
- 102000016553 Stearoyl-CoA Desaturase Human genes 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95459307P | 2007-08-08 | 2007-08-08 | |
| US60/954,593 | 2007-08-08 | ||
| PCT/IB2008/002028 WO2009019566A1 (en) | 2007-08-08 | 2008-07-28 | Phenoxy-pyrrolidine derivative and its use and compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0815048A2 true BRPI0815048A2 (pt) | 2016-04-05 |
| BRPI0815048B1 BRPI0815048B1 (pt) | 2020-09-29 |
| BRPI0815048B8 BRPI0815048B8 (pt) | 2021-05-25 |
Family
ID=39870001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0815048A BRPI0815048B8 (pt) | 2007-08-08 | 2008-07-28 | derivados de fenóxi-pirrolidinas, seus usos e composições farmacêuticas |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US8242286B2 (pt) |
| EP (1) | EP2173711B1 (pt) |
| JP (2) | JP5239001B2 (pt) |
| KR (1) | KR101189189B1 (pt) |
| CN (2) | CN101821234B (pt) |
| AT (1) | ATE488499T1 (pt) |
| AU (1) | AU2008285255B2 (pt) |
| BR (1) | BRPI0815048B8 (pt) |
| CA (1) | CA2695664C (pt) |
| DE (1) | DE602008003586D1 (pt) |
| ES (1) | ES2352098T3 (pt) |
| MX (1) | MX2010001485A (pt) |
| RU (1) | RU2010107892A (pt) |
| WO (1) | WO2009019566A1 (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2352098T3 (es) | 2007-08-08 | 2011-02-15 | Graceway Pharmaceuticals, Llc | Derivado de fenoxi-pirrolidina y su uso y composiciones. |
| FR2948939B1 (fr) | 2009-08-05 | 2013-03-22 | Pf Medicament | Derives de 2h pyridazin-3-ones, leur preparation et leur application en therapeutique humaine |
| FR2958935B1 (fr) * | 2010-04-19 | 2012-06-22 | Pf Medicament | Derives d'heterocycles azotes, leur preparation et leur application en therapeutique humaine |
| EP2579843A4 (en) | 2010-06-11 | 2015-12-16 | Avon Prod Inc | USE OF ECLIPTA PROSTRATA AND OTHER PPAR GAMMA INHIBITORS IN COSMETICS AND COMPOSITIONS THEREOF |
| MX2014004426A (es) | 2011-10-15 | 2014-07-09 | Genentech Inc | Metodos de uso de antagonistas de scd1. |
| US9233102B2 (en) | 2012-03-07 | 2016-01-12 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US10405795B1 (en) | 2013-03-15 | 2019-09-10 | The Procter & Gamble Company | Methods of classifying periorbital dyschromia and systems therefor |
| AU2014304079A1 (en) * | 2013-08-08 | 2016-02-25 | Galmed Research & Development Ltd. | Anti-acne compositions comprising bile acid-fatty acid conjugates |
| US9630896B2 (en) | 2013-11-22 | 2017-04-25 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-H/halo/ether-phenol compounds |
| EP4180041A1 (en) | 2014-08-07 | 2023-05-17 | Mayo Foundation for Medical Education and Research | Compounds and methods for treating cancer |
| KR20170000657U (ko) | 2015-08-11 | 2017-02-21 | 김유호 | 골프연습기 |
| EP3463277A4 (en) * | 2016-06-06 | 2020-01-01 | GDD Therapeutics, LLC | FORMULATIONS FOR SUBSTITUTED 3-PYRROLIDINES, COMPOSITIONS THEREFOR AND USES THEREOF |
| JP2019533022A (ja) | 2016-10-24 | 2019-11-14 | ユマニティ セラピューティクス，インコーポレーテッド | 化合物及びその使用 |
| CA3049010A1 (en) | 2017-01-06 | 2018-07-12 | Yumanity Therapeutics, Inc. | Methods for the treatment of neurological disorders |
| CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| CA3094527A1 (en) | 2018-03-23 | 2019-09-26 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| US12098146B2 (en) | 2019-01-24 | 2024-09-24 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| WO2022178261A1 (en) * | 2021-02-19 | 2022-08-25 | Lipidio Pharmaceuticals, Inc. | Methods for treating non-alcoholic steatohepatitis with a scd-1 inhibitor |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH432495A (de) * | 1964-02-04 | 1967-03-31 | Geigy Ag J R | Verfahren zur Herstellung neuer Aryloxyessigsäureamide |
| CA2067514A1 (en) | 1991-05-10 | 1992-11-11 | Sergiu Mircea Gorun | Manganese oligomer containing main group elements |
| US6338144B2 (en) | 1999-02-19 | 2002-01-08 | Sun Microsystems, Inc. | Computer system providing low skew clock signals to a synchronous memory unit |
| US20050119251A1 (en) | 2001-12-21 | 2005-06-02 | Jian-Min Fu | Nicotinamide derivatives and their use as therapeutic agents |
| ES2386354T3 (es) | 2003-07-29 | 2012-08-17 | Xenon Pharmaceuticals Inc. | Derivados de piridilo y su uso como agentes terapéuticos |
| EP3042895A1 (en) | 2003-07-30 | 2016-07-13 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| US7456180B2 (en) | 2003-07-30 | 2008-11-25 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their use as therapeutic agents |
| JP4782008B2 (ja) | 2003-07-30 | 2011-09-28 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ピリジル誘導体および治療剤としてのその用途 |
| HUP0401526A2 (en) * | 2004-07-29 | 2006-04-28 | Richter Gedeon Vegyeszet | Aryloxy acetic acid amide derivatives, pharmaceutical compositions comprising thereof, methods for their preparation and their use |
| US20090118296A1 (en) * | 2005-07-20 | 2009-05-07 | Merck Frosst Canada Ltd. | Heteroaromatic Compounds As Inhibitors Of Stearoyl-Coenzyme A Delta-9 Desaturase |
| JP2009539885A (ja) * | 2006-06-13 | 2009-11-19 | メルク フロスト カナダ リミテツド | ステアロイルコエンザイムａデルタ−９デサチュラーゼの阻害剤としてのアザシクロペンタン誘導体 |
| ES2352098T3 (es) | 2007-08-08 | 2011-02-15 | Graceway Pharmaceuticals, Llc | Derivado de fenoxi-pirrolidina y su uso y composiciones. |
-
2008
- 2008-07-28 ES ES08788986T patent/ES2352098T3/es active Active
- 2008-07-28 CN CN200880111278.9A patent/CN101821234B/zh active Active
- 2008-07-28 DE DE602008003586T patent/DE602008003586D1/de active Active
- 2008-07-28 JP JP2010519537A patent/JP5239001B2/ja active Active
- 2008-07-28 EP EP08788986A patent/EP2173711B1/en active Active
- 2008-07-28 CA CA2695664A patent/CA2695664C/en active Active
- 2008-07-28 BR BRPI0815048A patent/BRPI0815048B8/pt active IP Right Grant
- 2008-07-28 AT AT08788986T patent/ATE488499T1/de not_active IP Right Cessation
- 2008-07-28 CN CN201410216236.9A patent/CN104292144B/zh active Active
- 2008-07-28 WO PCT/IB2008/002028 patent/WO2009019566A1/en not_active Ceased
- 2008-07-28 AU AU2008285255A patent/AU2008285255B2/en not_active Ceased
- 2008-07-28 KR KR1020107001820A patent/KR101189189B1/ko active Active
- 2008-07-28 MX MX2010001485A patent/MX2010001485A/es not_active Application Discontinuation
- 2008-07-28 US US12/670,010 patent/US8242286B2/en active Active
- 2008-07-28 RU RU2010107892/04A patent/RU2010107892A/ru not_active Application Discontinuation
-
2012
- 2012-07-13 US US13/549,299 patent/US8524761B2/en active Active
-
2013
- 2013-03-05 JP JP2013043265A patent/JP5805119B2/ja active Active
- 2013-07-18 US US13/945,622 patent/US8980936B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP5805119B2 (ja) | 2015-11-04 |
| WO2009019566A1 (en) | 2009-02-12 |
| AU2008285255A1 (en) | 2009-02-12 |
| ATE488499T1 (de) | 2010-12-15 |
| BRPI0815048B8 (pt) | 2021-05-25 |
| CN101821234A (zh) | 2010-09-01 |
| JP2010535756A (ja) | 2010-11-25 |
| US8980936B2 (en) | 2015-03-17 |
| BRPI0815048B1 (pt) | 2020-09-29 |
| JP2013100377A (ja) | 2013-05-23 |
| US20140045911A1 (en) | 2014-02-13 |
| CN101821234B (zh) | 2014-06-25 |
| CA2695664A1 (en) | 2009-02-12 |
| US8524761B2 (en) | 2013-09-03 |
| AU2008285255B2 (en) | 2012-09-27 |
| CN104292144B (zh) | 2017-05-17 |
| KR101189189B1 (ko) | 2012-10-10 |
| US8242286B2 (en) | 2012-08-14 |
| US20120277280A1 (en) | 2012-11-01 |
| CA2695664C (en) | 2014-12-09 |
| CN104292144A (zh) | 2015-01-21 |
| EP2173711B1 (en) | 2010-11-17 |
| KR20100040878A (ko) | 2010-04-21 |
| DE602008003586D1 (de) | 2010-12-30 |
| US20100247471A1 (en) | 2010-09-30 |
| RU2010107892A (ru) | 2011-09-27 |
| ES2352098T3 (es) | 2011-02-15 |
| EP2173711A1 (en) | 2010-04-14 |
| JP5239001B2 (ja) | 2013-07-17 |
| MX2010001485A (es) | 2010-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010001485A (es) | Derivado de fenoxi-pirrolidina y su uso, y composiciones. | |
| EA201100049A1 (ru) | Органические соединения | |
| SMT201300098B (it) | Forme solide di N-(4-(7-azabiciclo[2.2.1]eptan-7-il)-2-(trifluorometil)fenil-4-osso-5-trifluorometil)-1,4-diidrochinolina-3-carbossammide | |
| BRPI0922073A2 (pt) | Compostos de éter com heterociclo de 5 membros contendo nitrogênio e usos dos mesmos. | |
| CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
| EA201001359A1 (ru) | Гетероциклические соединения в качестве ингибиторов cxcr2 | |
| BRPI0822929A2 (pt) | Composições compreendendo derivados de álcool benzílico e também compostos ativos antimicrobianos | |
| CL2011002781A1 (es) | Compuestos (e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol y (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol; composicion farmaceutica que los comprende; y uso en el tratamiento del cancer. | |
| ATE548374T1 (de) | 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren | |
| EA200900820A1 (ru) | 2-замещенные 5-членные гетероциклы в качестве ингибиторов стеароил-соа-десатуразы (ссд) | |
| CL2010001428A1 (es) | Compuestos derivados de amidas y tioamidas heteroaromaticas; agente que contiene al menos uno de dichos compuestos; procedimiento para combatir parasitos; y uso de dichos compuestos. | |
| CL2011001333A1 (es) | Compuestos derivados de heterociclos nitrogenados sustituidos, inhibidores de ns5a; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
| UY30610A1 (es) | Moduladores de mglur5 | |
| ATE516286T1 (de) | 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes | |
| MX354402B (es) | Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos. | |
| ATE496029T1 (de) | Derivate von 1-phenyl-2-pyridinylalkylenalkohole als phosphodiesteraseinhibitoren | |
| BRPI0813341A2 (pt) | " uso de compostos, composições curáveis, e, uso de composições curáveis ". | |
| DE602008005141D1 (de) | 1,3-dihydroimidazol-2-thionderivate als inhibitoren von dopamin-beta-hydroxylase | |
| EA200701396A1 (ru) | Триазолофталазины в качестве ингибиторов pde-2 | |
| CL2016001023A1 (es) | Compuesto n-(1-(4-(2-(4-cloro-2,6-dimetilpirimidin-5-il)etil)piperidin-1-il)-1-oxopropan-2-il)ciclopropanocarboxamida, estereoisomero, inhibidores de grelina o-aciltransferasa (goat); composición farmaceutica; y uso para reducir la ganancia de peso y para tratar la diabetes tipo 2. | |
| EP1718611A4 (en) | 3-3-DI-SUBSTITUTED OXINDOLES AS INHIBITORS OF INITIATION OF TRANSLATION | |
| CR11483A (es) | Inhibidores de peptido desformilasa | |
| UA106880C2 (uk) | Нові гербіциди | |
| DE602005023266D1 (de) | Azabenzofuransubstituierte thioharnstoffe als inhibitoren der virusreplikation | |
| MA32788B1 (fr) | 1-(arylsulfonyl)-4-(piperazine-1-yl)-1h-benzimidazoles servant de ligands de la 5-hydroxytryptamine-6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: MEDICIS PHARMACEUTICAL CORPORATION (US) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/09/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/07/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B25G | Requested change of headquarter approved |
Owner name: MEDICIS PHARMACEUTICAL CORPORATION (US) |
|
| B25A | Requested transfer of rights approved |
Owner name: THESAN PHARMACEUTICALS, INC. (US) |